Trial EudraCT021-002927-39
Publication Reindl-Schwaighofer R, JAMA, 2021
Primary outcome on the report: seroconversion rate (ie, detectable SARS-CoV-2 spike protein antibodies at a level >0.8 units [U]/mL) 4 weeks (29-42 days) following the third dose.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.